强生达雷妥尤单抗进入“百亿美元俱乐部”几乎已无悬念之际，蓄势已久的CD38药物终于在2025年开年展现出了燎原态势。 2025年的第二周，CD38靶点 ...

Central to the pathogenesis of VaD are cerebrovascular endothelial cell (CEC) dysfunction, blood-brain barrier (BBB) disruption, and neuroinflammation. CD38, an enzyme involved in neuroinflammation ...

赛诺菲今日宣布，旗下抗CD38单抗赛可益 ® （艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA）批准，用于与泊马度胺和地塞米松联合用药 ...

信达/康方/君实之后，恒瑞PCSK9单抗获批上市 赛诺菲抗CD38单抗在华上市，用于多发性骨髓瘤 1月9日，赛诺菲宣布旗下抗CD38单抗 ...

1月10日，康诺亚宣布，就潜在同类最优的靶向CD38人源化单克隆抗体CM313与Timberlyne Therapeutics达成独家授权许可协议。 CM313是由康诺亚自主研发的靶向 ...

Introduction: CD38, a regulator of intracellular calcium signalling, is highly expressed in immune cells. Mice lacking CD38 are very susceptible to acute bacterial infections, implicating CD38 in ...

However, an enzyme called CD38 breaks down the NAD, causing it to leak from cells. This leak gets accelerated with age and causes issues of aging and low energy levels. This MitoThrive formula is ...

More information: Bo Shi et al, Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in ...